Assessment of autonomic dysfunction with the COMPASS-31 and its relationship with disease activity and cardiovascular risks in patients with psoriatic arthritis

This study aimed to evaluate the autonomic dysfunction as assessed by the Composite Autonomic Symptom Score-31 (COMPASS-31) as well as its relationship with disease activity and cardiovascular risks in patients with psoriatic arthritis (PsA). This cross-sectional observational study involved 118 PsA...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatology international 2022-09, Vol.42 (9), p.1539-1548
Main Authors: Gezer, Halise Hande, Erdem Gürsoy, Didem, Acer Kasman, Sevtap, Duruöz, Mehmet Tuncay
Format: Article
Language:English
Subjects:
Body mass index
Cardiac arrhythmia
Cardiovascular disease
Cytokines
Diabetes
Heart attacks
Heart failure
Medicine
Medicine & Public Health
Metabolic syndrome
Nervous system
Observational Research
Observational studies
Pain
Patients
Psoriasis
Psoriatic arthritis
Quality of life
Rheumatic diseases
Rheumatology
Scleroderma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to evaluate the autonomic dysfunction as assessed by the Composite Autonomic Symptom Score-31 (COMPASS-31) as well as its relationship with disease activity and cardiovascular risks in patients with psoriatic arthritis (PsA). This cross-sectional observational study involved 118 PsA patients (85 females, mean age 45.6 years) and 64 healthy subjects. Cardiovascular risks were recorded including body mass index (BMI), hypertension (HT), diabetes mellitus (DM), dyslipidemia, metabolic syndrome (MetS), and 10-year Framingham Risk scores (FRS) were calculated. PsA was assessed with regard to disease activity, quality of life, and function. Autonomic dysfunction was evaluated using the COMPASS-31 consisting of six subdivisions including orthostatic, vasomotor, secretomotor, gastrointestinal, bladder, and pupillomotor functions. The mean disease duration was 63.3 months. The mean total COMPASS-31 score was significantly higher in PsA patients than in controls (24.4 vs 11.1; p  
ISSN:1437-160X
0172-8172
1437-160X
DOI:10.1007/s00296-022-05110-7